Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03319706
Recruitment Status : Completed
First Posted : October 24, 2017
Last Update Posted : October 24, 2017
Sponsor:
Information provided by (Responsible Party):
Torrent Pharmaceuticals Limited

Brief Summary:
Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were separated by a washout period of 7 days.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg Phase 1

Detailed Description:
An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose Bioequivalence Study of Olmesartan Medoxomil Tablets containing Olmesartan Medoxomil 40 mg (Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Benicar® 40 mg Tablets containing Olmesartan Medoxomil 40 mg (Reference, Daiichi Sankyo Inc., USA) in Healthy Human Volunteers Under Fed Condition.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fed Condition.
Study Start Date : August 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Test
Torrent's Olmesartan Medoxomil Tablets 40 mg
Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg
Active Comparator: Reference
Daiichi Sankyo Inc's Benicar Tablets 40 mg
Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg



Primary Outcome Measures :
  1. Cmax [ Time Frame: pre-dose to 72 hours post dose ]
  2. AUC [ Time Frame: pre-dose to 72 hours post dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males with age between 18-45 years (both inclusive)
  • Weight equal to or more than 50.00 Kgs
  • BMI 18.50 - 24.90 Kg/m2
  • Healthy as determined by medical history, clinical and laboratory examination performed within 21 days prior to admission day for the first period of the study.
  • Must have provided written informed consent for participation in the study in the subject's vernacular language
  • In the opinion of the Principal Investigator/Designee, be able to comply with the study procedures and protocol restrictions.

Exclusion Criteria:

  • Known hypersensitivity or idiosyncratic reaction to Olmesartan, its excipients or similar classes of drugs
  • Any evidence of significant abnormalities upon physical or clinical examination
  • Sitting blood pressure less than 100/70 mm Hg or more than 140/90 mm Hg and radical pulse rate less than 60 mm Hg or more than 100 mm Hg per minute at the time of screening.
  • Laboratory values, which are significantly different from predefined reference ranges and judged clinically significant.
  • Any clinically significant abnormality in ECG.
  • Any clinically significant abnormality in Chest X-ray (PA view)
  • Regular use of tobacco or nicotine in significant amount in any form (e.g. use of more than 10 cigarettes a day) or have difficulty in abstaining from [smoking] nicotine use for the duration of the study period.
  • History of drug dependence or excessive alcohol intake [subjects who drink more than 2 units per day (30 ml of 40% alcohol) or more than 14 units per week] on a habitual basis, or inability to abstain from alcohol for the duration of study period.
  • History or presence of serious gastrointestinal, liver, kidney, heart, lung, neurological or blood disease, diabetes or glaucoma.
  • History or presence of any chronic illnesses such as arthritis, asthma, epilepsy, hypertension etc.
  • Presence of disease markers of HIV 1 OR 2, Hepatitis B or C Viruses and VDRL.
  • Positive result for drug(s) of abuse testing (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opioids) in urine.
  • Positive test for alcohol breath analyzer test.
  • History and presence of any psychiatric illness.
  • History and presence of any illness including allergic skin diseases, allergic asthma and drug-induced allergy, e.g. NSAIDs
  • History of significant blood loss (≥ 350 mL) due to any reason, including blood donation within last 12 weeks prior to screening.
  • Existence of any surgical or medical condition which in the judgment of Principal Investigator/ Designee might interfere with the absorption, distribution, metabolism or excretion of the study drug, or, is likely to compromise the safety of subject.
  • Intake of any enzyme-modifying drugs such as cimetidine, theophylline, benzodiazepines, ranitidine, proton pump inhibitors, erythromycin, diuretics, ketoconazole, anti hypertensive drugs, dopamine agonists, etc within 30 days of study drug administration, or administration/ intake of any prescription or OTC drug including vitamins and natural supplements within 30 days of study drug administration. In such cases, enrolment of the subject in the study will be at the discretion of the Principal Investigator/designee.
  • Intake of unusual diet (e.g. low sodium) for two weeks prior to screening and throughout the subject's participation the study. In such case, subject selection will be at the discretion of the Principal investigator/ designee.

Layout table for additonal information
Responsible Party: Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT03319706     History of Changes
Other Study ID Numbers: OLME/10/027
First Posted: October 24, 2017    Key Record Dates
Last Update Posted: October 24, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Olmesartan
Olmesartan Medoxomil
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action